Dr Shammo on Future Research Investigating Combination Regimens in Myelofibrosis
Jamile M. Shammo, MD, discusses future directions for investigating JAK inhibitor–based combination regimens in transfusion-dependent myelofibrosis.
Related Articles
FDA Approves Perioperative Durvalumab Plus Chemo for Muscle-Invasive Bladder Cancer
The FDA approved perioperative durvalumab plus chemotherapy for muscle-invasive bladder cancer.
Five Under 5: Top Oncology Videos for the Week of 4/13
The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.
Nirogacestat Provides Long-Term Benefits in Desmoid Tumors
Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.
Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas
Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.
JAK Inhibitor Safety Is at the Heart of Treatment Selection in Myelofibrosis
Jamile M. Shammo, MD, discusses how the differences between the available JAK inhibitors in myelofibrosis guide her treatment considerations.
Itolizumab Misses Primary End Point in Acute GVHD but Shows Meaningful Improvements in Other Areas
The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3…
A Career in Clinical Development in Industry: Choose Your Own Adventure
Satya (Nanu) Das, MD, MSCI, pens this piece on what a career in drug development in the biopharmaceutical field may look like.
Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC
Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.
Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too
Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.
Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma
D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.